Jeffrey Stewart public
[search 0]
×
Best Jeffrey Stewart podcasts we could find (updated March 2020)
Best Jeffrey Stewart podcasts we could find
Updated March 2020
Join millions of Player FM users today to get news and insights whenever you like, even when you're offline. Podcast smarter with the free podcast app that refuses to compromise. Let's play!
Join the world's best podcast app to manage your favorite shows online and play them offline on our Android and iOS apps. It's free and easy!
More
show episodes
 
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved wi ...
 
Comedy writer/comic/author/radio personality/journalist Jeffrey Gurian brings you an inside look at the comedy world with interviews from the biggest A-list stars including Jimmy Fallon, Chelsea Handler, Jon Stewart, Seth Meyers, Nick Kroll, Bill Burr, Russell Peters, Amy Poehler, Lisa Lampanelli, Susie Essman and so many more! Mixed in with Jeffrey's take on the events of the day, and reports from GNN, (Gurian News Network) the most unusual stories from around the world missed by mainstream ...
 
Loading …
show series
 
A critical shortage of mechanical ventilators is anticipated in many countries, including the United States, because of the ongoing COVID-19 pandemic. A potential emergency solution would be the use of bi-level positive airway pressure (BiPAP). BiPAP may be used in the hospital setting with appropriate precautions for intubated COVID-19 patients ex…
 
In the midst of the COVID-19 pandemic, late stage clinical trials are at risk of disruption as shelter-in-place and more restrictive lockdown requirements roll out across the globe. How can these trials continue if patients can’t get to the clinic? In this episode in our Coronavirus Special Edition Series, Lou Boccumini, head of the infectious dise…
 
In the midst of a pandemic, industry is looking for ways to ensure continuity of clinical trials while keeping patients safe. Virtual approaches to clinical research leverage digital technologies to bring the study to the patient, and may be – in time – a viable option for limiting personal contact and possible spread of disease during outbreak sit…
 
As COVID-19 continues to spread worldwide, increasingly strict measures are being put into place in an attempt to slow it down while the scientific community pushes to identify effective antiviral options. In the second episode of our Coronavirus Special Edition series, Syneos Health infectious disease experts Gino Girardi, MD and Jaime E. Hernande…
 
The COVID-19 (coronavirus) outbreak continues to grow worldwide – recently declared by the World Health Organization as a global pandemic – with widespread personal, medical, and business implications. In this first episode of our Coronavirus Special Edition Series, we hear the personal experience of Dr. Siying Zou, a cell biologist on the Syneos H…
 
Recruiting patients into clinical trials is arguably one of the most, if not the most, important aspects of bringing a new therapy to market – and it can be the most difficult, time consuming part of the entire process. Clare Grace, Vice President, Site and Patient Access at Syneos Health discusses the challenges for patients when it comes to clini…
 
It may seem counter-intuitive to use the words “Commercial” and “Medical Affairs” in the same sentence. But with the evolution of Medical Affairs from a tactical support function to a strategy driving organization, it’s become clear that by partnering, the collective and complementary strengths of Medical Affairs and Commercial organizations will d…
 
Radical changes in the interface of health are rapidly changing where people find care. Where is that, exactly? Quick answer: everywhere. The point of care has been steadily shifting away from where the clinic exists to wherever the patient goes. Advances in digital care connections and the growth of new customer segments have opened up entirely ne…
 
FDA approval is no longer the finish line in the race to product launch success. Access and adoption have risen to the forefront as a major post-approval hurdle: recent research from Syneos Health Consulting’s Value and Access team shows that less than half of newly approved drugs appeared on formulary in their launch year. So what’s a drug develop…
 
As we’ve hammered home over the last several episodes of this series, Medical Affairs can bring great value to any moment in an asset’s life cycle. But there is one area where developers may be missing out on an opportunity to gain real traction in their efforts. Today we dive deeper into a Medical Affairs sweet spot with Steve Gomez, Senior Engage…
 
A striking life sciences trend has come into focus the past 12 months. Global regulators—often viewed as taking a conservative approach to transformative technology—have moved into the vanguard in discussions and guidance around real world data (RWD) and real world evidence (RWE). It is not so much the case with payers. According to new research by…
 
Earlier this year on Episode 040, we discussed the relatively new digital therapeutics landscape and the opportunities and challenges for both biopharma and tech companies. Today, we’ll take a deeper dive from the industry side – and specifically with a European perspective – with Jessica Shull, European Lead for the Digital Therapeutics Alliance, …
 
The Medical Science Liaison (MSL) has gone through a bit of an identity overhaul. A role that used to lean almost exclusively on scientific acumen must now more than ever also rely on business chops and people skills. A shift akin to moving from Geek Squad…to Apple Genius Bar. Keith Morris, Executive Managing Director, Medical Affairs at Syneos Hea…
 
Traditionally, Medical Affairs has served as a support function in later phases of product development, but they now need to play a more strategic and value-based role within the organization – and that means earlier and deeper engagement. In part three of our Medical Affairs Series, Suma Ramadas, Senior Managing Director and Colin Oliver, Director…
 
In this episode Sophia Stewart digs deeper into winning the case against the Wachowskis and the truth about white privilege in America. Follow Sophia Stewart of IG @motherofthematrix Get the original book called the Third Eye as well as the Matrix 4 Book at www.truthaboutmatrix.com Follow Anokhi The One on IG @Anokhitheone and take the Red Pill at …
 
In this Episode of Red Pill Radio our guest Sophia Stewart talks about winning the most influential case in Hollywood history, her engagement to Muhammad Ali and Will Smith's Serendipitous connection to the role of Neo. She even pitches the role of Neo to Will Smith and describes why the Wachowski's couldn't pitch it. Follow Sophia Stewart of IG @m…
 
Patients have been at the forefront of many of healthcare’s most historic moments—not just as subjects, but also as catalysts for change. Some of today’s advocates look to the early ACT UP years for inspiration; others turn to blueprints established by pioneers like Abbey Meyers or Kathy Guisti. In this episode, Keri McDonough, Lead, Advocacy and P…
 
No industry standard currently exists to measure value and impact of medical affairs, and the traditional metrics that companies often use to determine return on investment (ROI) simply don’t apply. In this second episode in our Medical Affairs series, Josh Samon, Managing Director and Colin Oliver, Director in Medical Affairs at Syneos Health Cons…
 
In this episode I will be diving deep into a subject that has propelled me to start businesses and communities of my own. That subject is Hollyweird gatekeepers! Thankfully they are finally being exposed and brought to light. I break down the psychology and the power structures that have made this possible in the past and how to dismantle them. I a…
 
Medical Affairs, once considered a support function, now has a seat at the table as one of the major pillars of biopharmaceutical organizations. So now what? Our new Medical Affairs series, which will unfold over the next several months, will explore what’s next and provide insights and best practices for “Next Gen” Medical Affairs. In this first e…
 
I start this episode with a Missy Elliott Tribute mix because I love the new Iconology Album :) Then I talk about Haters, Thieves and Learning From Adversity based on some recent incidences in my life. Then I mix some new music from Ashanti, Jidenna and Burna Boy. I end with my thoughts on Jay Z's NFL Deal.…
 
The need for real world evidence is growing beyond its original footprint of post-market intelligence, with uses now including regulatory approval, proof of value, maximized access and more. However, without a true understanding of the regulatory requirements around real world evidence, there is a risk of a “Goldilocks effect”— gathering either not…
 
In this episode we share our experience coming out to our family, our religious upbringing and how it effects us today. We also explore the spiritual gifts that LGBT have and how it's accepted and celebrated in spiritual practices like Santeria. Please welcome my guests Goddess Renee Angelique, The Wordmatician and Ebony Rose. Follow The Show on IG…
 
Not that kind of pie. In this case, PIE – or Preapproval Information Exchange – refers to the communication of clinical and health care economic information on therapies in development between U.S. population health decision makers and drug manufacturers prior to regulatory approval. John Seay, Vice President and Content Expert, Managed Markets Com…
 
In this episode we share our experience coming out to our family, our religious upbringing and how it effects us today. We also explore the spiritual gifts that LGBT have and how it's accepted and celebrated in spiritual practices like Santeria. Please welcome my guests Goddess Renee Angelique, The Wordmatician and Ebony Rose.…
 
Oncology continues to be one of the hottest therapeutic areas in the biopharmaceutical industry, but one that also poses some of the greatest challenges to developers. Jessica Lee, Ph.D., Managing Director in the Commercial Advisory Group at Syneos Health Consulting, discusses the most recent and promising innovations in oncology therapeutics, the …
 
When it comes to clinical trials, what do clinical psychologists bring to the table? Quite a lot, says Alexandria Wise-Rankovic, Ph.D., a clinical psychologist and Senior Vice President, Clinical Development in the CNS Business Unit at Syneos Health. In this episode, Dr. Wise-Rankovic discusses the important role of the clinical psychologist in cli…
 
The biopharmaceutical market has evolved quite a bit over the last five to 10 years. As more emerging companies are opting to commercialize on their own, they can no longer look to the “tried and true,” traditional strategies for bringing a therapy to market – those rules no longer apply. So what’s the new normal, and what does it mean for this new…
 
The infrastructure we rely on to create new medicines is in sore need of an upgrade. More and more investigational drugs are streaming into the pipeline. But most of them fail in clinical trials, draining corporate resources, disappointing investors, and shattering the hopes of patients. Financially speaking, return on investment (ROI) for R&D in b…
 
Research in the area of live biotherapeutics has exploded in the last seven years. There is still much to learn about whether a dysregulated gut microbiome (dysbiosis) causes disease, or whether disease leads to dysbiosis – but the potential for significant contribution to healthcare is there. Erin Mistry, Senior Managing Director, and Thunicia Moo…
 
The role of Medical Affairs has changed dramatically in China over the last 10-15 years, moving from what was once considered a secondary support function to one now at the forefront of a more patient-centric paradigm. Sam Ying, Vice President and General Manager for Syneos Health Commercial in China, discusses the evolution of the Medical Affairs …
 
The art of communications in the pharmaceutical industry is becoming more complex. According to Amy Hutnik, Chief Growth and Transformation Officer for Syneos Health Communications, we’ve evolved from the point of DTC (Direct to Consumer) to the extremely individualized opportunity of DT“Me” (Direct to Me). The landscape has changed dramatically in…
 
New regulations, which were adopted on May 26, 2017, will affect all device and diagnostics manufacturers looking to sell products in the EU, with stricter requirements being introduced in order for these products to be approved. We are just over a year out from implementation of some of these European Union Medical Device Regulations (EUMDR), set …
 
In this first episode of the Syneos Health Podcast: APAC Edition, host Robbie Chana speaks with Sebastian Bather, President of APAC in Japan for Syneos Health, about key trends in Asia Pacific with potentially high impact on the biopharmaceutical industry in the region, including significant growth and change in regulation in China, great interest …
 
According to the Syneos Health 2019 Health Trend Ten, perhaps the biggest shift for 2019 and beyond is global focus on understanding what product differentiation looks like in real-world environments. In Europe in particular, countries are implementing more stringent measures that will impact how value is assigned in the future – and real world evi…
 
Big changes are happening in Asia, opening up a world of possibilities for biopharmaceutical companies to accelerate clinical development of innovative medicines. Robbie Chana, Vice President, Business Development, Asia Pacific talks about the unique opportunity for biopharma in the region, such as regulatory and financial incentives for innovation…
 
A commercial model built to deliver blockbuster drugs to the market is no longer effective – particularly for delivering therapies for complex disease states to smaller, more targeted patient populations and specialty providers. But what will the new, “commercial model of the future” look like? There’s no one clear answer, but Howard Brock, Senior …
 
The treatment of cancer has undergone a sea change in the span of a generation. In this two-part episode for World Cancer Day, we discuss the increasingly complex oncology landscape, from both a clinical and clinician perspective. First, Bob Millham, Executive Vice President of Clinical Development and head of our Oncology Center of Excellence, add…
 
It’s just one word. But it carries the weight of over 43 million people, about a quarter which spends 41 hours or more per week providing care for loved ones with medical conditions. Caregivers are not just influencers for healthcare decision-making; many are the decision makers, according to Carolyn Stephenson, SVP, Director of Insights, and Ilya …
 
As we head toward the close of the year, we are already looking to see what 2019 has in store. Drawing on the knowledge and experience of more than 200 leaders and experts who work on the front lines of healthcare, we identified 10 critical shifts that will change how we test and commercialize novel new therapies and innovations in the years ahead.…
 
As we head toward the close of the year, we are already looking to see what 2019 has in store. Drawing on the knowledge and experience of more than 200 leaders and experts who work on the front lines of healthcare, we identified 10 critical shifts that will change how we test and commercialize novel new therapies and innovations in the years ahead.…
 
In our increasingly digital world, it was only a matter of time before search and social marketing would start to take on an important role in clinical trial patient recruitment. But with shaken trust in data security combined with sensitivities around medical data privacy, will potential patients click? Matthew Snodgrass and Michael Pearlman from …
 
Clinical trials are arguably the largest investment a biopharma company makes in bringing a product to market - in dollars, and time. Driving the stakes higher: the patient is waiting. How can we improve the process, realize shorter and more efficient trials, and ultimately get the therapy to that patient faster? Syneos Health Clinical Solutions ex…
 
Loading …
Google login Twitter login Classic login